Atlas Trials

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Clinical trial NCT01399125 · COMPLETED

Trial details

NCT number
NCT01399125
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Alzheimer's Disease
Start date
2011-07-01
Primary completion
2013-05-01
Enrollment
501

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.